In a patient with sarcoidosis who has signs or symptoms of cardiac involvement, what is the recommended diagnostic work‑up and treatment plan?

Cardiac Sarcoidosis: Diagnostic Work-up and Treatment

Diagnostic Approach

For patients with sarcoidosis who have signs or symptoms of cardiac involvement, cardiac MRI is the recommended first-line imaging modality, and treatment with glucocorticoids (with or without other immunosuppressives) should be initiated immediately for any functional cardiac abnormalities including heart block, dysrhythmias, or cardiomyopathy. 1

Initial Diagnostic Testing

When cardiac involvement is suspected based on symptoms (palpitations, syncope, chest pain, dyspnea) or signs (arrhythmias, heart block, heart failure):

• Cardiac MRI is the preferred imaging test to establish the diagnosis 2

  • Provides detailed assessment of myocardial inflammation, scarring (late gadolinium enhancement), and ventricular function
  • High sensitivity for detecting cardiac involvement

• If cardiac MRI is unavailable, use dedicated FDG-PET imaging rather than echocardiography for diagnostic and prognostic information 2

  • FDG-PET is superior for identifying active inflammation
  • Particularly useful for monitoring treatment response

• Baseline ECG should be performed in all patients with extracardiac sarcoidosis, even without cardiac symptoms 2

• Echocardiography has a limited role in initial diagnosis but may be used for:

  • Assessing ventricular function and wall motion abnormalities
  • Evaluating for pulmonary hypertension if suspected clinically

Endomyocardial Biopsy

While endomyocardial biopsy provides definitive histologic diagnosis, it has low sensitivity due to patchy myocardial involvement 3, 4. It is reserved for:

• Cases where imaging is inconclusive
• When giant cell myocarditis must be excluded
• Isolated cardiac presentations without extracardiac disease confirmation

Treatment Algorithm

First-Line Therapy: Glucocorticoids

Glucocorticoids (with or without other immunosuppressives) are strongly recommended for all patients with functional cardiac abnormalities 1

• Starting dose: Prednisolone 0.5 mg/kg/day is as effective as higher doses 1
• Higher doses (>0.5 mg/kg) provide no additional benefit 1
• Earlier initiation of glucocorticoids is associated with better cardiac outcomes 1
• Continuous treatment is critical—withdrawal of glucocorticoids after initiation, even with clinical improvement, leads to worse outcomes 1

Critical pitfall: Heart block often responds best to glucocorticoids and may be the manifestation with the highest chance of reversibility 1. Do not delay treatment.

Steroid-Sparing Agents

Early initiation of steroid-sparing medications should be considered to limit glucocorticoid toxicity 1

For patients with:

• Continued disease despite glucocorticoids
• Unacceptable glucocorticoid side effects
• Need for prolonged immunosuppression

Options include:

• Methotrexate: Most commonly used; one retrospective study showed improved ejection fraction and brain natriuretic peptide after 5 years when added to prednisone 1
• Azathioprine
• Mycophenolate mofetil
• Leflunomide
• Cyclophosphamide

Third-Line: Biologic Therapy

Infliximab (TNF inhibitor) may be useful for refractory disease not responding to glucocorticoids and conventional immunosuppressants 1

Concurrent Cardiac Management

Beyond immunosuppression, address:

1. Arrhythmia management:

   • Antiarrhythmic medications as needed
   • Implantable cardioverter-defibrillator (ICD) for patients with:
     • Left ventricular ejection fraction <40%
     • Ventricular tachycardia
     • Survivors of sudden cardiac arrest

2. Heart failure therapy:

   • Guideline-directed medical therapy for reduced ejection fraction
   • ACE inhibitors/ARBs, beta-blockers, mineralocorticoid receptor antagonists

3. Pacemaker for symptomatic atrioventricular block

Prognostic Factors Requiring Aggressive Treatment

Patients with these features warrant more intensive monitoring and treatment 1:

• Age >50 years
• Left ventricular ejection fraction <40%
• NYHA Class III or IV heart failure
• Increased left ventricular end-diastolic diameter
• Late gadolinium enhancement on cardiac MRI
• Ventricular tachycardia
• Cardiac inflammation on FDG-PET
• Abnormal global longitudinal strain on echo
• Interventricular septal thinning
• Elevated troponin or BNP

Key Clinical Pitfalls

1. Do not wait for biopsy confirmation before starting treatment in symptomatic patients—the risk of sudden cardiac death is high 1

2. Do not discontinue glucocorticoids prematurely—even with apparent clinical improvement, withdrawal worsens outcomes 1

3. Do not perform routine screening echocardiography or Holter monitoring in asymptomatic patients with extracardiac sarcoidosis—baseline ECG is sufficient 2

4. Do not use echocardiography alone for diagnosis when cardiac involvement is suspected—cardiac MRI or FDG-PET are far superior 2

5. Consider genetic cardiomyopathy evaluation in isolated cardiac presentations, as genetic conditions can mimic cardiac sarcoidosis 3

Monitoring Treatment Response

• FDG-PET is the preferred modality for assessing active inflammation and guiding immunosuppressive therapy adjustments 5
• Cardiac MRI is better for assessing morphology, function, and fibrosis
• Combined use of both modalities is more effective than either alone 5